<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35316145</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1555-8576</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer biology &amp; therapy</Title>
          <ISOAbbreviation>Cancer Biol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>NEDD4L inhibits glycolysis and proliferation of cancer cells in oral squamous cell carcinoma by inducing ENO1 ubiquitination and degradation.</ArticleTitle>
        <Pagination>
          <StartPage>243</StartPage>
          <EndPage>253</EndPage>
          <MedlinePgn>243-253</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/15384047.2022.2054244</ELocationID>
        <Abstract>
          <AbstractText>Glycolysis contributes to cell metabolism and facilitates cell proliferation of oral squamous cell carcinoma (OSCC), the most common type of oral cancer. Understanding the regulatory mechanisms involved in the glycolysis of OSCC cells may provide important therapeutic inspirations. Immunohistochemistry was used to examine protein localization patterns in human OSCC tissues and Western blot was conducted to gauge protein level. Lentivirus transduction was used to overexpress or silence genes of interest. Cell proliferation was assessed by Cell Counting Kit (CCK)-8 assay while glycolysis was examined via measurement of extracellular acidification rate, oxygen consumption rate, and lactate and ATP production. <i>In vivo</i> cancer development was evaluated with a mouse tumor growth model. OSCC tissues displayed reduced expression of NEDD4L compared with normal tissues. NEDD4L expression positively correlated with 5-year patient survival rate, indicating that NEDD4L may be a prognosis marker for OSCC. NEDD4L overexpression suppressed proliferation, cell cycle transition, and glycolysis in OSCC cells, and inhibited <i>in vivo</i> tumor growth. UbiBrowser identified ENO1, an enzyme that catalyzes glycolysis, as a substrate of NEDD4L. Overexpression of NEDD4L resulted in the ubiquitination and subsequent degradation of ENO1 whereas overexpression of ENO1 reversed the functional effects of NEDD4L overexpression, restoring proliferation, cell cycle transition, and glycolysis in OSCC cells. NEDD4L elicits tumor-suppressive functions via inhibition of OSCC cell proliferation, cell cycle transition, and glycolysis by stimulating ENO1 ubiquitination and degradation. Our results unraveled a signaling axis important for OSCC cell survival and metabolism, which can serve as a potential therapeutic target.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Guangping</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0003-3879-9439</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Oral and Maxillofacial Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School and Hospital of Stomatology, China Medical University, Liaoning Provincial Key Laboratory of Oral Diseases, Shenyang, Liaoning, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Weixian</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0003-1219-0182</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Oral and Maxillofacial Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cancer Biol Ther</MedlineTA>
        <NlmUniqueID>101137842</NlmUniqueID>
        <ISSNLinking>1538-4047</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 4.2.1.11</RegistryNumber>
          <NameOfSubstance UI="C095157">ENO1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 4.2.1.11</RegistryNumber>
          <NameOfSubstance UI="D010751">Phosphopyruvate Hydratase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002294" MajorTopicYN="Y">Carcinoma, Squamous Cell</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006019" MajorTopicYN="N">Glycolysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009062" MajorTopicYN="Y">Mouth Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010751" MajorTopicYN="N">Phosphopyruvate Hydratase</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077195" MajorTopicYN="N">Squamous Cell Carcinoma of Head and Neck</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054875" MajorTopicYN="N">Ubiquitination</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Cell cycle</Keyword>
        <Keyword MajorTopicYN="Y">ENO1</Keyword>
        <Keyword MajorTopicYN="Y">glycolysis</Keyword>
        <Keyword MajorTopicYN="Y">proliferation</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>17</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35316145</ArticleId>
        <ArticleId IdType="pmc">PMC8942561</ArticleId>
        <ArticleId IdType="doi">10.1080/15384047.2022.2054244</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Markopoulos AK.
Current aspects on oral squamous cell carcinoma. The Open Dentistry Journal. 2012;6:126–130. doi:10.2174/1874210601206010126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1874210601206010126</ArticleId>
            <ArticleId IdType="pmc">PMC3428647</ArticleId>
            <ArticleId IdType="pubmed">22930665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campbell CD, Mohajeri K, Malig M, Hormozdiari F, Nelson B, Du G, Patterson KM, Eng C, Torgerson DG, Hu D, et al. Whole-genome sequencing of individuals from a founder population identifies candidate genes for asthma. PloS one. 2014;9:e104396. doi:10.1371/journal.pone.0104396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0104396</ArticleId>
            <ArticleId IdType="pmc">PMC4130548</ArticleId>
            <ArticleId IdType="pubmed">25116239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee DE, Yoo JE, Kim J, Kim S, Kim S, Lee H, Cheong H. NEDD4L downregulates autophagy and cell growth by modulating ULK1 and a glutamine transporter. Cell Death &amp; Disease. 2020;11:38. doi:10.1038/s41419-020-2242-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-2242-5</ArticleId>
            <ArticleId IdType="pmc">PMC6971022</ArticleId>
            <ArticleId IdType="pubmed">31959741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye X, Wang L, Shang B, Wang Z, Wei W. NEDD4: a promising target for cancer therapy. Current Cancer Drug Targets. 2014;14:549–556. doi:10.2174/1568009614666140725092430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1568009614666140725092430</ArticleId>
            <ArticleId IdType="pmc">PMC4302323</ArticleId>
            <ArticleId IdType="pubmed">25088038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Q, Zhao J, Cui M, Gi S, Wang W, Han X. Nedd4L expression is decreased in ovarian epithelial cancer tissues compared to ovarian non-cancer tissue. The Journal of Obstetrics and Gynaecology Research. 2015;41:1959–1964. doi:10.1111/jog.12808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jog.12808</ArticleId>
            <ArticleId IdType="pubmed">26554540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He S, Deng J, Li G, Wang B, Cao Y, Tu Y. Down-regulation of Nedd4L is associated with the aggressive progression and worse prognosis of malignant glioma. Japanese Journal of Clinical Oncology. 2012;42:196–201. doi:10.1093/jjco/hyr195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jjco/hyr195</ArticleId>
            <ArticleId IdType="pubmed">22217575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang X, Zhang S, Yin Z, Sheng Y, Yan Q, Sun R, Lu M, Zhang Z, Li Y. The correlation between NEDD4L and HIF-1alpha levels as a gastric cancer prognostic marker. International Journal of Medical Sciences. 2019;16:1517–1524. doi:10.7150/ijms.34646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/ijms.34646</ArticleId>
            <ArticleId IdType="pmc">PMC6818201</ArticleId>
            <ArticleId IdType="pubmed">31673244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu XY, Xu YM, Fu Q, Yu JJ, Huang J. Nedd4L expression is downregulated in prostate cancer compared to benign prostatic hyperplasia. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2009;35:527–531. doi:10.1016/j.ejso.2008.09.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejso.2008.09.015</ArticleId>
            <ArticleId IdType="pubmed">19004604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao C, Pang L, Ren C, Ma T. Decreased expression of Nedd4L correlates with poor prognosis in gastric cancer patient. Medical Oncology. 2012;29:1733–1738. doi:10.1007/s12032-011-0061-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12032-011-0061-3</ArticleId>
            <ArticleId IdType="pubmed">21909941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yilmaz E, Gul M, Melekoglu R, Inci Coskun E, Sahin N, Gul S, Bastemur AG, Ciplak B. Neural precursor cell-expressed developmentally down-regulated 4-like: a new biomarker in the pathophysiology of endometrial cancer. The Journal of International Medical Research. 2018;46:3709–3716. doi:10.1177/0300060518777944.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0300060518777944</ArticleId>
            <ArticleId IdType="pmc">PMC6136009</ArticleId>
            <ArticleId IdType="pubmed">29998764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao F, Gong X, Liu A, Lv X, Hu B, Zhang H. Downregulation of Nedd4L predicts poor prognosis, promotes tumor growth and inhibits MAPK/ERK signal pathway in hepatocellular carcinoma. Biochemical and Biophysical Research Communications. 2018;495:1136–1143. doi:10.1016/j.bbrc.2017.11.139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2017.11.139</ArticleId>
            <ArticleId IdType="pubmed">29175326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H, Zhu J, Wang G, Liu H, Zhou Y, Qian J. STK35 Is ubiquitinated by NEDD4L and promotes glycolysis and inhibits apoptosis through regulating the AKT signaling pathway, influencing chemoresistance of colorectal cancer. Frontiers in Cell and Developmental Biology. 2020;8:582695. doi:10.3389/fcell.2020.582695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2020.582695</ArticleId>
            <ArticleId IdType="pmc">PMC7578231</ArticleId>
            <ArticleId IdType="pubmed">33117809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanksley JP, Chen X, Coffey RJ, Liu C. NEDD4L is downregulated in colorectal cancer and inhibits canonical WNT signaling. PloS one. 2013;8:e81514. doi:10.1371/journal.pone.0081514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0081514</ArticleId>
            <ArticleId IdType="pmc">PMC3842946</ArticleId>
            <ArticleId IdType="pubmed">24312311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Novellasdemunt L, Kucharska A, Jamieson C, Prange-Barczynska M, Baulies A, Antas P, van der Vaart J, Gehart H, Maurice MM, Li VS, et al. NEDD4 and NEDD4L regulate Wnt signalling and intestinal stem cell priming by degrading LGR5 receptor. The EMBO Journal. 2020;39:e102771. doi:10.15252/embj.2019102771.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embj.2019102771</ArticleId>
            <ArticleId IdType="pmc">PMC6996568</ArticleId>
            <ArticleId IdType="pubmed">31867777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen JM, Chiu SC, Chen KC, Huang YJ, Liao YA, Yu CR. Enolase 1 differentially contributes to cell transformation in lung cancer but not in esophageal cancer. Oncology Letters. 2020;19:3189–3196. doi:10.3892/ol.2020.11427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2020.11427</ArticleId>
            <ArticleId IdType="pmc">PMC7074250</ArticleId>
            <ArticleId IdType="pubmed">32256815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuo J, Wang B, Long M, Gao Z, Zhang Z, Wang H, Wang X, Li R, Dong K, Zhang H, et al. The type 1 transmembrane glycoprotein B7-H3 interacts with the glycolytic enzyme ENO 1 to promote malignancy and glycolysis in HeLa cells. FEBS Letters. 2018;592:2476–2488. doi:10.1002/1873-3468.13164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1873-3468.13164</ArticleId>
            <ArticleId IdType="pubmed">29924389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang T, Shu X, Zhang HW, Sun LX, Yu L, Liu J, Sun L-C, Yang Z-H, Ran Y-L. Enolase 1 regulates stem cell-like properties in gastric cancer cells by stimulating glycolysis. Cell Death &amp; Disease. 2020;11:870. doi:10.1038/s41419-020-03087-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-03087-4</ArticleId>
            <ArticleId IdType="pmc">PMC7567818</ArticleId>
            <ArticleId IdType="pubmed">33067426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Molecular Cancer. 2013;12:152. doi:10.1186/1476-4598-12-152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-12-152</ArticleId>
            <ArticleId IdType="pmc">PMC4223729</ArticleId>
            <ArticleId IdType="pubmed">24298908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nowak N, Kulma A, Gutowicz J. Up-regulation of key glycolysis proteins in cancer development. Open Life Sciences. 2018;13:569–581. doi:10.1515/biol-2018-0068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1515/biol-2018-0068</ArticleId>
            <ArticleId IdType="pmc">PMC7874691</ArticleId>
            <ArticleId IdType="pubmed">33817128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin H, Wang L, Liu HL. ENO1 overexpression in pancreatic cancer patients and its clinical and diagnostic significance. Gastroenterology Research and Practice. 2018;2018:3842198. doi:10.1155/2018/3842198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2018/3842198</ArticleId>
            <ArticleId IdType="pmc">PMC5816842</ArticleId>
            <ArticleId IdType="pubmed">29483925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song Y, Luo Q, Long H, Hu Z, Que T, Zhang X, Li Z, Wang G, Yi L, Liu Z, et al. Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma. Molecular Cancer. 2014;13:65. doi:10.1186/1476-4598-13-65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-13-65</ArticleId>
            <ArticleId IdType="pmc">PMC3994408</ArticleId>
            <ArticleId IdType="pubmed">24650096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li HJ, Ke FY, Lin CC, Lu MY, Kuo YH, Wang YP, Liang K-H, Lin S-C, Chang Y-H, Chen H-Y, et al. ENO1 promotes lung cancer metastasis via HGFR and WNT signaling-driven epithelial-mesenchymal transition. Cancer Research. 2021;81:4094–4109. doi:10.1158/0008-5472.CAN-20-3543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-20-3543</ArticleId>
            <ArticleId IdType="pubmed">34145039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsiao KC, Shih NY, Fang HL, Huang TS, Kuo CC, Chu PY, Hung Y-M, Chou S-W, Yang -Y-Y, Chang G-C, et al. Surface alpha-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target. PloS one. 2013;8:e69354. doi:10.1371/journal.pone.0069354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0069354</ArticleId>
            <ArticleId IdType="pmc">PMC3716638</ArticleId>
            <ArticleId IdType="pubmed">23894455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Principe M, Borgoni S, Cascione M, Chattaragada MS, Ferri-Borgogno S, Capello M, Bulfamante S, Chapelle J, Di Modugno F, Defilippi P, et al. Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. Journal of Hematology &amp; Oncology. 2017;10:16. doi:10.1186/s13045-016-0385-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-016-0385-8</ArticleId>
            <ArticleId IdType="pmc">PMC5237223</ArticleId>
            <ArticleId IdType="pubmed">28086938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Yang Q, Sun H, Wang X, Saiyin H, Zhang H. The circ-AMOTL1/ENO1 axis implicated in the tumorigenesis of OLP-associated oral squamous cell carcinoma. Cancer Management and Research. 2020;12:7219–7230. doi:10.2147/CMAR.S251348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CMAR.S251348</ArticleId>
            <ArticleId IdType="pmc">PMC7440838</ArticleId>
            <ArticleId IdType="pubmed">32884340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu F, Shi X, Zhang R, Tian Y, Wang X, Wei C, Li D, Li X, Kong X, Liu Y, et al. Regulation of proliferation and cell cycle by protein regulator of cytokinesis 1 in oral squamous cell carcinoma. Cell Death &amp; Disease. 2018;9:564. doi:10.1038/s41419-018-0618-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-018-0618-6</ArticleId>
            <ArticleId IdType="pmc">PMC5948203</ArticleId>
            <ArticleId IdType="pubmed">29752448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Reviews in Molecular Medicine. 2008;10:e19. doi:10.1017/S1462399408000744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S1462399408000744</ArticleId>
            <ArticleId IdType="pmc">PMC2678956</ArticleId>
            <ArticleId IdType="pubmed">18590585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shamloo B, Usluer S. p21 in cancer research. Cancers. 2019;11:1178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6721478</ArticleId>
            <ArticleId IdType="pubmed">31416295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Q, Al-Hendy A. The emerging role of p27 in development of diseases. Cancer Studies and Molecular Medicine: Open Journal. 2018;4:e1–e3. doi:10.17140/CSMMOJ-4-e006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.17140/CSMMOJ-4-e006</ArticleId>
            <ArticleId IdType="pmc">PMC6247914</ArticleId>
            <ArticleId IdType="pubmed">30474063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu L, Chen X, Sun X, Wang L, Chen S. The glycolytic switch in tumors: how many players are involved?
Journal of Cancer. 2017;8:3430–3440. doi:10.7150/jca.21125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/jca.21125</ArticleId>
            <ArticleId IdType="pmc">PMC5687156</ArticleId>
            <ArticleId IdType="pubmed">29151926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Dang T, Liu T, Chen S, Li L, Huang S, Fang M. NEDD4L protein catalyzes ubiquitination of PIK3CA protein and regulates PI3K-AKT signaling. The Journal of Biological Chemistry. 2016;291:17467–17477. doi:10.1074/jbc.M116.726083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M116.726083</ArticleId>
            <ArticleId IdType="pmc">PMC5016142</ArticleId>
            <ArticleId IdType="pubmed">27339899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mookerjee SA, Brand MD. Measurement and analysis of extracellular acid production to determine glycolytic rate. Journal of Visualized Experiments: JoVE. 2015:e53464. 10.3791/53464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3791/53464</ArticleId>
            <ArticleId IdType="pmc">PMC4692795</ArticleId>
            <ArticleId IdType="pubmed">26709455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pelletier M, Billingham LK, Ramaswamy M, Siegel RM. Extracellular flux analysis to monitor glycolytic rates and mitochondrial oxygen consumption. Methods in Enzymology. 2014;542:125–149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24862264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X, Kaufman PD. Ki-67: more than a proliferation marker. Chromosoma. 2018;127:175–186. doi:10.1007/s00412-018-0659-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00412-018-0659-8</ArticleId>
            <ArticleId IdType="pmc">PMC5945335</ArticleId>
            <ArticleId IdType="pubmed">29322240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Didiasova M, Schaefer L, Wygrecka M. When place matters: shuttling of enolase-1 across cellular compartments. Frontiers in Cell and Developmental Biology. 2019;7:61. doi:10.3389/fcell.2019.00061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2019.00061</ArticleId>
            <ArticleId IdType="pmc">PMC6498095</ArticleId>
            <ArticleId IdType="pubmed">31106201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nandi D, Tahiliani P, Kumar A, Chandu D. The ubiquitin-proteasome system. Journal of Biosciences. 2006;31:137–155. doi:10.1007/BF02705243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02705243</ArticleId>
            <ArticleId IdType="pubmed">16595883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goel P, Manning JA, Kumar S. NEDD4-2 (NEDD4L): the ubiquitin ligase for multiple membrane proteins. Gene. 2015;557:1–10. doi:10.1016/j.gene.2014.11.051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2014.11.051</ArticleId>
            <ArticleId IdType="pmc">PMC6636357</ArticleId>
            <ArticleId IdType="pubmed">25433090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu L, Chen J, Cai X, Yao Z, Huang J. Progress in targeted therapeutic drugs for oral squamous cell carcinoma. Surgical Oncology. 2019;31:90–97. doi:10.1016/j.suronc.2019.09.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.suronc.2019.09.001</ArticleId>
            <ArticleId IdType="pubmed">31550560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li M, Gao F, Zhao Q, Zuo H, Liu W, Li W. Tanshinone IIA inhibits oral squamous cell carcinoma via reducing Akt-c-Myc signaling-mediated aerobic glycolysis. Cell Death &amp; Disease. 2020;11:381. doi:10.1038/s41419-020-2579-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-2579-9</ArticleId>
            <ArticleId IdType="pmc">PMC7235009</ArticleId>
            <ArticleId IdType="pubmed">32424132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei J, Wu J, Xu W, Nie H, Zhou R, Wang R, Liu Y, Tang G, Wu J. Salvianolic acid B inhibits glycolysis in oral squamous cell carcinoma via targeting PI3K/AKT/HIF-1alpha signaling pathway. Cell Death &amp; Disease. 2018;9:599. doi:10.1038/s41419-018-0623-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-018-0623-9</ArticleId>
            <ArticleId IdType="pmc">PMC5964095</ArticleId>
            <ArticleId IdType="pubmed">29789538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han L, Cheng J, Li A. hsa_circ_0072387 suppresses proliferation, metastasis, and glycolysis of oral squamous cell carcinoma cells by downregulating miR-503-5p. Cancer Biotherapy &amp; Radiopharmaceuticals. 2021;36:84–94. doi:10.1089/cbr.2019.3371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cbr.2019.3371</ArticleId>
            <ArticleId IdType="pubmed">32302508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng M, Cao MX, Yu XH, Li L, Wang K, Wang SS, Wang H-F, Tang Y-J, Tang Y-L, Liang X-H, et al. STAT3 promotes invasion and aerobic glycolysis of human oral squamous cell carcinoma via inhibiting FoxO1. Frontiers in Oncology. 2019;9:1175. doi:10.3389/fonc.2019.01175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2019.01175</ArticleId>
            <ArticleId IdType="pmc">PMC6848388</ArticleId>
            <ArticleId IdType="pubmed">31750256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salah Z, Cohen S, Itzhaki E, Aqeilan RI. NEDD4 E3 ligase inhibits the activity of the Hippo pathway by targeting LATS1 for degradation. Cell Cycle. 2013;12:3817–3823. doi:10.4161/cc.26672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cc.26672</ArticleId>
            <ArticleId IdType="pmc">PMC3905073</ArticleId>
            <ArticleId IdType="pubmed">24107629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakata T, Sakaguchi H, Tsuda L, Higashitani A, Aigaki T, Matsuno K, Hayashi S. Drosophila Nedd4 regulates endocytosis of notch and suppresses its ligand-independent activation. Current Biology: CB. 2004;14:2228–2236. doi:10.1016/j.cub.2004.12.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2004.12.028</ArticleId>
            <ArticleId IdType="pubmed">15620649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo X-Y, Liu -T-T, Zhu W-J, Liu H-T, Zhang G-H, Song L. CircKDM4B suppresses breast cancer progression via the miR-675/NEDD4L axis. Oncogene
2022:1–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">35145234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guarnieri A, Towers C, Drasin D, Oliphant M, Andrysik Z, Hotz T, Vartuli RL, Linklater ES, Pandey A, Khanal S, et al. The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L. Oncogene. 2018;37:3879–3893. doi:10.1038/s41388-018-0239-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-018-0239-7</ArticleId>
            <ArticleId IdType="pmc">PMC6043359</ArticleId>
            <ArticleId IdType="pubmed">29662198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klement RJ, Kammerer U. Is there a role for carbohydrate restriction in the treatment and prevention of cancer?
Nutrition &amp; Metabolism. 2011;8:75. doi:10.1186/1743-7075-8-75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1743-7075-8-75</ArticleId>
            <ArticleId IdType="pmc">PMC3267662</ArticleId>
            <ArticleId IdType="pubmed">22029671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Molecular Cancer Therapeutics. 2012;11:1672–1682. doi:10.1158/1535-7163.MCT-12-0131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-12-0131</ArticleId>
            <ArticleId IdType="pubmed">22689530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vander Heiden MG, Christofk HR, Schuman E, Subtelny AO, Sharfi H, Harlow EE, Xian J, Cantley LC. Identification of small molecule inhibitors of pyruvate kinase M2. Biochemical Pharmacology. 2010;79:1118–1124. doi:10.1016/j.bcp.2009.12.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2009.12.003</ArticleId>
            <ArticleId IdType="pmc">PMC2823991</ArticleId>
            <ArticleId IdType="pubmed">20005212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Price GS, Page RL, Riviere JE, Cline JM, Thrall DE. Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs. Cancer Chemotherapy and Pharmacology. 1996;38:129–135. doi:10.1007/s002800050460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s002800050460</ArticleId>
            <ArticleId IdType="pubmed">8616902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Zhang P, Wei Y, Piao HL, Wang W, Maddika S, Wang M, Chen D, Sun Y, Hung M-C, et al. Deubiquitylation and stabilization of PTEN by USP13. Nat Cell Biol. 2013;15:1486–1494. doi:10.1038/ncb2874.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb2874</ArticleId>
            <ArticleId IdType="pmc">PMC3951854</ArticleId>
            <ArticleId IdType="pubmed">24270891</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
